Torray Investment Partners LLC Buys 1,767 Shares of The Cooper Companies, Inc. (NASDAQ:COO)

Torray Investment Partners LLC grew its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 12.5% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 15,888 shares of the medical device company’s stock after buying an additional 1,767 shares during the quarter. Torray Investment Partners LLC’s holdings in Cooper Companies were worth $1,387,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of COO. Benjamin F. Edwards & Company Inc. lifted its stake in shares of Cooper Companies by 248.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 244 shares of the medical device company’s stock worth $25,000 after acquiring an additional 174 shares during the period. Innealta Capital LLC bought a new position in Cooper Companies during the 2nd quarter worth approximately $25,000. Covestor Ltd boosted its stake in shares of Cooper Companies by 305.9% in the 1st quarter. Covestor Ltd now owns 276 shares of the medical device company’s stock valued at $28,000 after purchasing an additional 208 shares during the last quarter. Crewe Advisors LLC boosted its stake in shares of Cooper Companies by 286.4% in the 2nd quarter. Crewe Advisors LLC now owns 340 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 252 shares during the last quarter. Finally, Global Retirement Partners LLC increased its position in shares of Cooper Companies by 358.6% during the first quarter. Global Retirement Partners LLC now owns 321 shares of the medical device company’s stock worth $33,000 after buying an additional 251 shares during the period. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Cooper Companies

In other news, CFO Brian G. Andrews sold 24,788 shares of the company’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $105.90, for a total transaction of $2,625,049.20. Following the sale, the chief financial officer now directly owns 6,614 shares in the company, valued at $700,422.60. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, COO Daniel G. Mcbride sold 114,992 shares of the business’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $105.48, for a total transaction of $12,129,356.16. Following the completion of the transaction, the chief operating officer now directly owns 44,696 shares in the company, valued at $4,714,534.08. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Brian G. Andrews sold 24,788 shares of the firm’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $105.90, for a total value of $2,625,049.20. Following the completion of the sale, the chief financial officer now directly owns 6,614 shares in the company, valued at approximately $700,422.60. The disclosure for this sale can be found here. Corporate insiders own 2.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on COO. Needham & Company LLC reaffirmed a “hold” rating on shares of Cooper Companies in a research note on Thursday, August 29th. Piper Sandler raised their price objective on shares of Cooper Companies from $115.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, August 29th. Stifel Nicolaus reiterated a “buy” rating and issued a $115.00 price objective (up previously from $110.00) on shares of Cooper Companies in a research note on Thursday, August 29th. Jefferies Financial Group upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating and raised their price target for the stock from $107.00 to $115.00 in a report on Tuesday, July 16th. Finally, Wells Fargo & Company upped their price objective on shares of Cooper Companies from $110.00 to $115.00 and gave the company an “overweight” rating in a report on Thursday, August 29th. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, Cooper Companies has a consensus rating of “Moderate Buy” and an average target price of $113.61.

Cooper Companies Stock Performance

NASDAQ COO traded up $0.09 during trading hours on Friday, reaching $106.59. 1,235,653 shares of the company were exchanged, compared to its average volume of 1,128,133. The stock has a market capitalization of $21.22 billion, a P/E ratio of 62.70, a P/E/G ratio of 2.56 and a beta of 0.98. The company has a quick ratio of 1.14, a current ratio of 1.99 and a debt-to-equity ratio of 0.33. The Cooper Companies, Inc. has a 1 year low of $75.93 and a 1 year high of $107.82. The business’s 50 day simple moving average is $93.30 and its 200-day simple moving average is $94.65.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings data on Wednesday, August 28th. The medical device company reported $0.96 earnings per share for the quarter, beating the consensus estimate of $0.91 by $0.05. Cooper Companies had a return on equity of 9.08% and a net margin of 9.45%. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $997.30 million. During the same period in the prior year, the company earned $0.84 earnings per share. Cooper Companies’s revenue was up 7.8% compared to the same quarter last year. On average, equities research analysts expect that The Cooper Companies, Inc. will post 3.66 earnings per share for the current year.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.